FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... September 10, 2021 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His... January 21, 2022 Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... June 17, 2020 Load more HOT NEWS Why I Choose to Live With Gratitude During Metastatic Breast Cancer Melanoma Cells Are More Likely to Spread after a Stopover in... Bringing a Piece of Home to the Hospital ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery
